Add to ORKGOur results show that everolimus delays mammary tumor formation in multiple mouse models, suggesting that mTOR inhibitors will be useful for the prevention of ER-negative and triple-negative breast cancer in humans. See related Spotlight, p. 787
Background: The mammalian target of rapamycin (mTOR) protein is important for cellular growth and ho...
Hormone receptor–positive breast cancer is typically managed with endocrine therapies. However, resi...
The mTOR inhibitor, everolimus, is an important clinical management component of metastatic ER+ brea...
Despite minimal activity as single agents, mTOR inhibitors are currently in advanced phases of clini...
<div><p>The mammalian target of rapamycin (mTOR), a vital component of signaling pathways involving ...
The mammalian target of rapamycin (mTOR), a vital component of signaling pathways involving PI3K/AKT...
The mammalian target of rapamycin (mTOR), a vital component of signaling pathways involving PI3K/AKT...
Breast cancer is a heterogeneous group of diseases that are clinically subdivided as hormone recepto...
Resistance to endocrine therapy in breast cancer is associated with activation of the mammalian targ...
Everolimus, an mTOR inhibitor, showed great clinical efficacy in combination with tamoxifen, letrozo...
AbstractAlthough patients with hormone receptor (HR)–positive breast cancer are successfully treated...
The mTOR pathway is pivotal not only in tumorigenesis but also in chemotherapy and hormonal drug sen...
Triple-negative breast cancers (TNBC) are characterized by frequent alterations in the PI3K/AKT/mTOR...
Improvements in survival of patients with breast cancer have been attributed to the development of a...
Many systemic treatment options are available for advanced breast cancer, including endocrine therap...
Background: The mammalian target of rapamycin (mTOR) protein is important for cellular growth and ho...
Hormone receptor–positive breast cancer is typically managed with endocrine therapies. However, resi...
The mTOR inhibitor, everolimus, is an important clinical management component of metastatic ER+ brea...
Despite minimal activity as single agents, mTOR inhibitors are currently in advanced phases of clini...
<div><p>The mammalian target of rapamycin (mTOR), a vital component of signaling pathways involving ...
The mammalian target of rapamycin (mTOR), a vital component of signaling pathways involving PI3K/AKT...
The mammalian target of rapamycin (mTOR), a vital component of signaling pathways involving PI3K/AKT...
Breast cancer is a heterogeneous group of diseases that are clinically subdivided as hormone recepto...
Resistance to endocrine therapy in breast cancer is associated with activation of the mammalian targ...
Everolimus, an mTOR inhibitor, showed great clinical efficacy in combination with tamoxifen, letrozo...
AbstractAlthough patients with hormone receptor (HR)–positive breast cancer are successfully treated...
The mTOR pathway is pivotal not only in tumorigenesis but also in chemotherapy and hormonal drug sen...
Triple-negative breast cancers (TNBC) are characterized by frequent alterations in the PI3K/AKT/mTOR...
Improvements in survival of patients with breast cancer have been attributed to the development of a...
Many systemic treatment options are available for advanced breast cancer, including endocrine therap...
Background: The mammalian target of rapamycin (mTOR) protein is important for cellular growth and ho...
Hormone receptor–positive breast cancer is typically managed with endocrine therapies. However, resi...
The mTOR inhibitor, everolimus, is an important clinical management component of metastatic ER+ brea...